Medicare AdvantageCoverageMedium impact
MA08.144b, Tezepelumab-ekko (Tezspire®)
Independence Blue Cross·Pulmonology, Allergy & Immunology, Family Medicine +2 more·Pharmacy
Effective date
Aug 6, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.144b for Tezepelumab-ekko (Tezspire®) has been reissued with updates effective August 6, 2025. This is a pharmacy policy change that may affect coverage, prior authorization, or billing requirements for this asthma medication.
Action Required
By August 6, 2025: Billing team should review the full policy details at the provided URL to understand specific changes to Tezepelumab-ekko (Tezspire®) coverage requirements. Update prior authorization procedures and billing protocols for Medicare Advantage patients receiving this asthma medication as needed based on the complete policy content.